What Synjardy Treats: Main Uses and Benefits

Synjardy is commonly used as an adjunct to diet and exercise to address symptoms related to systemic imbalance, specifically inadequate glycemic control in adults and pediatric patients (aged 10 years and older) with Type 2 Diabetes Mellitus. This medication is applied across domains where additional symptomatic support is needed. It helps manage the complex symptom clusters that arise from the condition, including poor blood sugar regulation, established cardiovascular disease, and chronic kidney disease.

The combination is relevant when supportive symptom management is appropriate and helps with maintaining functional stability. A relevant therapeutic domain is used for managing the cardiovascular system in patients who also have established heart and blood vessel disease. The medication may assist with reducing the risk of serious cardiovascular events and hospitalization due to heart failure.

“The goal is to provide supportive relief during symptomatic phases related to chronic metabolic stress.”

It is also considered relevant in contexts involving heightened systemic burden on the kidneys, as it is commonly used to help with managing symptoms linked to organ-specific functional stress by reducing the risk of complications. This contributes to maintaining functional stability and supports general well-being during symptomatic periods.

---

Quick Fact: Relief for Metabolic Symptoms
Main Conditions	Type 2 Diabetes Mellitus, Established Cardiovascular Disease, Chronic Kidney Disease
Primary Benefit	Contributes to metabolic stability and assists with serious complication risk reduction
Use Context	Applied when single-agent therapy is sub-optimal or when support for cardiovascular and renal health is relevant

---

Regulatory References

1. NIH DailyMed Label for Synjardy

This section outlines the eligibility and exclusion criteria for Synjardy (empagliflozin and metformin hydrochloride) as defined in official regulatory documents.

Populations Excluded from Use (Contraindicated)

The medicine is contraindicated in patients with:

• Severe renal impairment (estimated GFR or eGFR <30 mL/min/1.73 m^2), end-stage renal disease (ESRD), or those on dialysis.
• Any form of acute or chronic metabolic acidosis, including diabetic ketoacidosis.
• A history of serious hypersensitivity reaction to either empagliflozin, metformin, or any excipients.
• Acute conditions that may potentially alter renal function (e.g., dehydration, shock, severe infection) or cause tissue hypoxia (e.g., respiratory failure, decompensated heart failure) (EMA).
• Hepatic impairment (EMA/FDA).

Restricted and Non-Recommended Populations

Use is not recommended for improving glycemic control in patients with Type 1 Diabetes Mellitus due to the increased risk of ketoacidosis. Initiation is not recommended in patients with an eGFR less than 45 mL/min/1.73 m^2 due to the metformin component. The medicine is officially limited to patients with Type 2 Diabetes Mellitus for all indications.

Age and Physiological States:

• Pediatric use is allowed for patients aged 10 years and older with Type 2 Diabetes Mellitus (FDA). Safety and efficacy are not established in children under 10.
• Pregnancy and Lactation: The medicine is not recommended when breastfeeding, and use during the second and third trimesters of pregnancy may carry potential risks to the fetus.
• Procedures: The medicine must be temporarily discontinued before or during procedures involving iodinated contrast media or surgery associated with prolonged fasting or restricted food/fluid intake.

Interactions with other medicines and products

Official regulatory documents classify interactions for Synjardy (Empagliflozin/Metformin) based on effects related to drug exposure, pharmacodynamic action, and procedural constraints.

Key Interaction Classifications

Interaction Type	Interacting Substances/Context	Official Outcome/Restriction
Reduced Renal Clearance	Ranolazine, Vandetanib, Dolutegravir, Cimetidine	Co-administration may increase the systemic exposure of metformin by inhibiting renal transporters, raising the risk of lactic acidosis.
Additive Glycemic Effect	Insulin, Sulfonylureas	Co-administration results in an additive blood sugar lowering effect [Official Risk: Hypoglycemia].
Volume/Electrolyte Risk	Diuretics (Loop/Thiazide), Lithium, Carbonic Anhydrase Inhibitors (e.g., Topiramate)	Diuretics enhance potential for volume depletion; Empagliflozin may decrease serum lithium levels. Carbonic Anhydrase Inhibitors may increase acidosis risk.

Procedural and Substance Restrictions

• Iodinated Contrast Media: Synjardy must be temporarily discontinued at the time of or prior to radiological studies using iodinated contrast media in patients with specific risk factors (e.g., eGFR below 60 mL/min/1.73 m^2).
• Surgical Procedures: Temporary discontinuation is required for any surgical procedure necessitating restricted food and fluid intake.
• Excessive Alcohol Intake: Formally cautioned against as it potentiates the effect of metformin on lactate metabolism, which increases the risk of lactic acidosis.
• Food/Vitamin B12: The medication should be taken with meals. Metformin may interfere with Vitamin B12 absorption, resulting in documented decreased serum B12 levels.

This structure defines the mandatory restrictions and required timing separations for use with other products, as stated in regulatory prescribing information.

The mechanism of action for Synjardy is achieved through the complementary actions of its two components, targeting distinct physiological pathways for plasma glucose modulation.

The Empagliflozin component acts as a selective competitive inhibitor of the Sodium-Glucose Co-Transporter 2 (SGLT2) protein, a key transporter found in the proximal renal tubules of the kidney. By blocking SGLT2, the drug causes filtered glucose to be excreted into the urine (glucosuria). This provides a direct, insulin-independent mechanism that results in a reduction of systemic plasma glucose concentration.

Simultaneously, the Metformin component modulates glucose supply and utilization. It acts in the liver by indirectly activating the AMP-activated protein kinase (AMPK) enzyme, which suppresses the expression of enzymes necessary for hepatic gluconeogenesis (the creation of new glucose). Concurrently, Metformin enhances the responsiveness of peripheral tissues, such as muscle cells, to insulin signals, thereby promoting cellular uptake of circulating glucose. The combination of increased renal removal and decreased hepatic production modulates overall glucose homeostasis.

Official Administration Guidelines

Synjardy (empagliflozin and metformin hydrochloride) is an oral medication with specific administration rules based on its formulation. The immediate-release (IR) tablet is taken twice daily with meals. The extended-release (XR) tablet, branded as Synjardy XR, is taken once daily with a meal in the morning.

Dosing and Preparation

• Dosing: The starting dose is individualized based on the patient's current regimen of empagliflozin and/or metformin. The maximum recommended total daily dose is 25 mg of empagliflozin and 2000 mg of metformin HCl. Dose escalation must be gradual to minimize gastrointestinal issues related to the metformin component.
• Preparation: Synjardy XR tablets must be swallowed whole. They must not be split, crushed, dissolved, or chewed.
• Missed Dose: If a dose is missed, patients should take it as soon as they remember. However, a double dose should not be taken at the next scheduled time; the missed dose should be skipped to resume the normal schedule.

Procedural Requirements

Prior to starting the medication and periodically thereafter, renal function (eGFR) must be assessed. Initiation is not recommended in adult or pediatric patients with an eGFR persistently below 45 mL/min/1.73 m^2 due to the metformin component.

The medication must be temporarily discontinued at the time of or prior to iodinated contrast imaging procedures in patients with an eGFR below 60 mL/min/1.73 m^2. The drug must also be withheld, if possible, for at least 3 days prior to surgery or procedures associated with prolonged fasting. Correcting volume depletion (dehydration) is required before initiation of therapy.

Research Evidence / Overview of Studies

Synjardy is a fixed-dose combination of empagliflozin and metformin. Clinical studies have evaluated the combination's use in adults with type 2 diabetes mellitus (T2DM), often comparing it to placebo or the individual components.

Efficacy Studies: Glycemic Control

Studies evaluated the effect of the drug on markers of blood sugar control. In randomized, double-blind trials, participants who were taking metformin alone and had inadequate glycemic control were given either empagliflozin (10 mg or 25 mg) or a placebo for 24 weeks. Key findings included:

Outcome Measured	Empagliflozin + Metformin	Placebo + Metformin
Change in HbA1c (avg.)	Reduction of 0.70% to 0.77%	Reduction of 0.13%
Change in Body Weight (avg.)	Reduction of 2.08 kg to 2.46 kg	Reduction of 0.45 kg

These studies demonstrated that the addition of empagliflozin to metformin resulted in a measured change in both Hemoglobin A1c (HbA1c) and body weight compared to placebo plus metformin.

Cardiovascular Outcomes

Evidence for the empagliflozin component of Synjardy (Jardiance) from the EMPA-REG OUTCOME trial showed a reduction in the risk of cardiovascular death in adults with T2DM and established cardiovascular disease. However, the effectiveness of the Synjardy combination product specifically on reducing the risk of cardiovascular death has not been established in its own dedicated study.

Pediatric Use

Recent trials have also examined empagliflozin's use in children aged 10 years and older with T2DM. A study demonstrated a significant reduction in HbA1c compared to placebo, leading to the approval of the combination for this pediatric population. Safety findings in pediatric participants were generally consistent with those observed in adults, though a higher risk of hypoglycemia was noted in this age group, regardless of other concurrent diabetes therapies.

Common questions about Synjardy (FAQ)

---

Q: Does Synjardy affect kidney function long-term?

Official studies indicate that the empagliflozin component of this medicine is indicated to reduce the risk of a sustained decline in kidney function for eligible adults who also have chronic kidney disease.

However, regulatory documents require frequent monitoring of kidney function during treatment due to the risk of acute changes associated with the medication's components.

---

Q: Is Synjardy appropriate for people who are taking blood pressure medication?

Official product information indicates that patients who are taking medications to lower their blood pressure, particularly certain water pills (diuretics), may face an increased risk.

This is because the drug can enhance volume depletion (dehydration), leading to symptomatic low blood pressure.

---

Q: What are the most commonly reported reasons for discontinuing Synjardy?

During clinical trials, the most commonly reported adverse reactions were gastrointestinal disorders, such as diarrhea, nausea, and vomiting. Genital mycotic infections, which include yeast infections, were also commonly reported.

These common adverse events are generally noted at the start of treatment.

---

Q: Does Synjardy have any known interactions with herbal supplements or vitamins?

Regulatory information notes that metformin, one of the active components, may interfere with the body's absorption of Vitamin B12. Due to this potential decrease in B12 levels over time, official documents state that regular monitoring of blood B12 levels may be necessary for some patients.

---

Q: Is Synjardy considered a high-risk medication for older adults?

Official safety information indicates that older adults may have a higher risk of certain adverse reactions compared to younger populations. This includes reactions related to dehydration (volume depletion) and issues related to decreased kidney function. Regulatory documents necessitate more frequent safety monitoring in this age group.

---

Q: Can Synjardy cause yeast infections, and if so, why?

The empagliflozin component of the medicine works by causing the body to excrete more sugar through the urine. This process, called glucosuria, creates a sugar-rich environment in the urogenital area.

According to regulatory sources, this environment can increase the risk of developing genital mycotic infections, such as yeast infections.

---

Q: Why does the label mention a risk of lactic acidosis?

The warning about lactic acidosis is directly linked to the metformin component of the medication. Official sources explain that metformin can increase lactate levels by slowing the clearance of lactate and interfering with certain metabolic processes.

This risk becomes significantly higher if a patient's kidney function is impaired.

---

Q: How does Synjardy compare to just taking empagliflozin alone?

Studies examined the effect of the combined medication versus using empagliflozin alone. The results indicated that the combination product was associated with a reduction in hemoglobin A1c (HbA1c), a key measure of long-term blood sugar control, that was numerically lower compared to using empagliflozin alone.

---

Q: Is the research evidence for Synjardy considered strong or limited?

The regulatory approval for the medication is based on data from specific randomized, double-blind, placebo-controlled clinical trials.

These types of studies are the primary basis for regulatory drug approval and evaluated the drug's effectiveness in improving blood sugar control and measured outcomes like cardiovascular risk.

---

Q: Can Synjardy be taken if a person has certain types of heart conditions?

Official information states that the empagliflozin component is indicated to reduce the risk of cardiovascular death in adults with established cardiovascular disease.

It is also indicated to reduce the risk of cardiovascular death and hospitalization for heart failure. Contraindications mainly focus on acute conditions such as decompensated heart failure.

---

Q: Why is it important to check for ketones while on Synjardy?

According to regulatory warnings, the medication carries a risk of diabetic ketoacidosis (DKA), a serious condition that requires immediate attention.

DKA is diagnosed by finding an increase in ketones in the blood or urine. Official labels advise checking for ketones if a patient develops symptoms of metabolic acidosis.

---

Q: What does 'adjunctive therapy' mean in the context of Synjardy's use?

The term "adjunctive therapy" means that the medication is intended to be used in addition to other primary treatments.

Specifically, the regulatory documents state that the medicine is indicated as an adjunct to diet and exercise to help improve blood sugar control in patients with Type 2 diabetes.

---

Q: Are there different strengths of Synjardy, and what determines the strength prescribed?

The medication is available in multiple different strengths, representing varying combinations of the two active ingredients.

Official guidelines state that the specific dose prescribed is individualized. This is determined based on the patient's existing regimen, the effectiveness achieved, and their tolerability of the medicine.

---

Q: Why are people with severe renal impairment generally not allowed to use Synjardy?

Use is strictly contraindicated in patients with severe kidney impairment. Regulatory warnings explain that the metformin component is mainly eliminated by the kidneys, so impairment leads to the accumulation of the drug in the body.

This accumulation significantly increases the risk of developing a rare but serious condition called lactic acidosis.

---

Q: What is the difference between Synjardy and Synjardy XR?

The primary difference lies in the release format and typical dosing schedule.

Synjardy is an immediate-release tablet typically prescribed for twice-daily administration with meals. Synjardy XR is an extended-release formulation generally prescribed for once-daily administration with a meal.

---

Q: Why would a doctor prescribe Synjardy instead of separate pills for the two ingredients?

Synjardy is classified as a fixed-dose combination product, meaning both active ingredients are contained in a single tablet.

Regulatory documents note that the combination is designed to leverage two distinct, complementary mechanisms to more comprehensively regulate blood sugar than a single medicine alone.

---

Q: Are there specific food types that interact negatively with Synjardy?

Official documents typically state the medication should be taken with meals to help reduce potential stomach side effects.

Regulatory sources also contain cautions regarding excessive alcohol intake and the need for temporary discontinuation before procedures that involve prolonged fasting.

---

Q: What kind of studies have been done on the long-term safety of Synjardy?

The components of the medication have been the subject of long-term clinical trials. These studies, which cover extended periods, have evaluated the drug's effectiveness, measured cardiovascular outcomes, and monitored for potential adverse events that may occur over time.

---

Q: Can Synjardy affect fertility or reproductive health?

Official documents contain a warning for premenopausal females about the potential for unintended pregnancy.

This is noted because improved blood sugar control, which the medication helps achieve, may lead to a return to ovulation in patients who were previously anovulatory.

---

Q: Does Synjardy cause fatigue or low energy levels in some users?

Official safety documents list weakness, medically referred to as asthenia, as one of the common side effects reported with the use of this medication.

---

Q: Can Synjardy affect the results of other medical lab tests?

The metformin component of the drug is known to potentially interfere with the absorption of Vitamin B12.

This can result in decreased B12 levels in the blood, and monitoring of B12 levels via lab tests may be required in some cases.

---

Q: What evidence is there regarding Synjardy's effect on blood pressure?

Regulatory information notes that the medication may cause symptomatic hypotension, which is a drop in blood pressure.

This effect is a result of volume depletion (dehydration) and is of particular concern in at-risk populations.

---

Q: Does Synjardy interact with common medications for heartburn or acid reflux?

Official drug interaction information notes that certain medications used to treat heartburn or acid reflux, such as Cimetidine, can affect the body's processing of metformin.

These interactions may increase the amount of metformin in the body by inhibiting certain kidney transporters.

---

Q: Are there any official warnings about driving or operating machinery while on Synjardy?

There are specific warnings regarding the risk of hypoglycemia, or low blood sugar, especially when the medicine is used along with insulin or a sulfonylurea.

The official documents state that this risk should be considered as it may affect a person's ability to safely drive or operate complex machinery.

How to Store and Dispose of Synjardy

Synjardy tablets must be stored according to official regulatory conditions to ensure product stability and safety. The medication is required to be stored at Controlled Room Temperature, specifically at 25 C (77 F), with permitted temperature variations between 15 C and 30 C (59 F and 86 F).

Storage and Child Safety

• The product must be kept in its original container, tightly closed, and stored in a dry place away from excess moisture and heat.
• A mandatory safety requirement is that Synjardy must be kept out of the sight and reach of children.

Disposal

Official disposal instructions prohibit discarding the medicine in wastewater or household trash. Unused or expired medication must be disposed of in accordance with local regulations, often by returning it to a pharmacist or a recognized drug take-back program.